Si è verificato un errore durante il caricamento della pagina.
Il nostro team è stato avvisato ma contattaci tramite il Widget assistenza email se il problema persiste.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 14,3x - 15,8x | 15,0x |
| Selected Fwd Revenue Multiple | 13,7x - 15,1x | 14,4x |
| Fair Value | ₩2.557 - ₩2.816 | ₩2.686 |
| Upside | -2,2% - 7,7% | 2,7% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| HLB Pep Co., Ltd. | A196300 | KOSDAQ:A196300 |
| SCM Lifescience Co., Ltd. | A298060 | KOSDAQ:A298060 |
| GeneOne Life Science, Inc. | A011000 | KOSE:A011000 |
| Genome & Company | A314130 | KOSDAQ:A314130 |
| Daesung Microbiological Labs. Co., Ltd. | A036480 | KOSDAQ:A036480 |
| PeopleBio, Inc. | A304840 | KOSDAQ:A304840 |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| A196300 | A298060 | A011000 | A314130 | A036480 | A304840 | |||
| KOSDAQ:A196300 | KOSDAQ:A298060 | KOSE:A011000 | KOSDAQ:A314130 | KOSDAQ:A036480 | KOSDAQ:A304840 | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | -0.2% | 37.4% | -2.8% | 260.1% | -1.1% | NM- | ||
| 3Y CAGR | -15.3% | 23.4% | -2.6% | 294.7% | -0.3% | 86.3% | ||
| Latest Twelve Months | -25.1% | 41.8% | -6.6% | 94.1% | -7.9% | -16.2% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -54.8% | -2881.8% | -85.2% | -3537.1% | -0.4% | -494.6% | ||
| Prior Fiscal Year | -119.7% | -1868.3% | -120.3% | -385.4% | -2.7% | -342.4% | ||
| Latest Fiscal Year | -87.3% | -1371.0% | -120.5% | -87.2% | -6.5% | -308.2% | ||
| Latest Twelve Months | -120.6% | -816.1% | -110.3% | -87.2% | -6.6% | -308.2% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 14.60x | 24.05x | 8.65x | 2.96x | 1.78x | 14.39x | ||
| EV / LTM EBIT | -12.1x | -2.9x | -7.8x | -3.4x | -26.8x | -4.7x | ||
| Price / LTM Sales | 16.94x | 20.51x | 7.95x | 2.86x | 1.34x | 14.92x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 1.78x | 8.65x | 24.05x | |||||
| Historical EV / LTM Revenue | 14.39x | 31.05x | 256.28x | |||||
| Selected EV / LTM Revenue | 14.26x | 15.01x | 15.76x | |||||
| (x) LTM Revenue | 3,732 | 3,732 | 3,732 | |||||
| (=) Implied Enterprise Value | 53,224 | 56,026 | 58,827 | |||||
| (-) Non-shareholder Claims * | 1,991 | 1,991 | 1,991 | |||||
| (=) Equity Value | 55,215 | 58,017 | 60,818 | |||||
| (/) Shares Outstanding | 21.2 | 21.2 | 21.2 | |||||
| Implied Value Range | 2,608.14 | 2,740.46 | 2,872.78 | |||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2,608.14 | 2,740.46 | 2,872.78 | 2,615.00 | ||||
| Upside / (Downside) | -0.3% | 4.8% | 9.9% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A196300 | A298060 | A011000 | A314130 | A036480 | A304840 | |
| Enterprise Value | 72,194 | 28,304 | 324,381 | 82,620 | 41,898 | 53,370 | |
| (+) Cash & Short Term Investments | 17,504 | 2,714 | 3,944 | 80,930 | 8,555 | 6,393 | |
| (+) Investments & Other | 1 | 0 | 17 | 0 | 1,620 | 4,372 | |
| (-) Debt | (6,244) | (6,857) | (30,171) | (32,024) | (20,343) | (9,252) | |
| (-) Other Liabilities | 0 | 0 | 0 | (50,753) | 0 | 773 | |
| (-) Preferred Stock | 0 | 0 | 0 | (883) | 0 | (295) | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 83,455 | 24,162 | 298,171 | 79,890 | 31,730 | 55,361 | |
| (/) Shares Outstanding | 9.3 | 28.7 | 84.7 | 31.1 | 3.8 | 21.2 | |
| Implied Stock Price | 8,980.00 | 841.00 | 3,520.00 | 2,570.00 | 8,350.00 | 2,615.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 8,980.00 | 841.00 | 3,520.00 | 2,570.00 | 8,350.00 | 2,615.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |